12.75GBp0.00%Mkt Cap: 15.94M GBpP/E: —Last update: 2026-06-01
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap15.94M GBp
Enterprise Value14.63M GBp
Revenue (TTM)1.60M GBp
Gross Profit430.00K GBp
Net Income (TTM)-1.71M GBp
Revenue/Share0.0150 GBp
Last Price12.75 GBp
Fiscal Year EndMar 2025
MR QuarterSep 2025
Employees24
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.17
PEG—
EV/EBITDA-10.46
EV/Revenue9.16
P/S9.99
P/B21.25
EPS (TTM)-0.02
EPS (Forward)-0.01
52W Range
0.000061% of range21.00
52W High21.00 GBp
52W Low0.0000 GBp
Profitability
Gross Margin21.88%
Oper. Margin-64.44%
EBITDA Margin-87.59%
Profit Margin-87.18%
ROE-256.05%
ROA-129.48%
Growth
Revenue Growth-30.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.36M GBp
CapEx (TTM)10.00K GBp
FCF Margin-48.68%
FCF Yield-4.87%
Net Debt136.00K GBp
Net Debt/EBITDA-0.10
Balance Sheet
Debt/Equity0.03
Current Ratio1.80
Quick Ratio1.45
Book Value/Sh0.0060 GBp
Cash/Share0.0020 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.125.02M
Float99.08M
Insiders11.59%
Institutions27.51%
Technical
SMA 5013.42 (-5.0%)
SMA 20014.14 (-9.8%)
Beta1.20
S&P 52W Chg27.94%
Avg Vol (30d)477.37K
Avg Vol (10d)291.11K
Technical Indicators
RSI (14)42.5
MACD-0.1903
MACD Signal-0.0334
MACD Hist.-0.1569
BB Upper15.25 GBp
BB Middle13.58 GBp
BB Lower11.92 GBp
BB Width24.46%
ATR (14)2.011 GBp
Vol Ratio (20d)0.96x